Venus Medtech Valuation

VMTHF Stock  USD 0.27  0.03  10.00%   
Venus Medtech seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Venus Medtech from inspecting the company fundamentals such as Return On Equity of -0.11, operating margin of (1.18) %, and Shares Outstanding of 441.01 M as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
0.27
Please note that Venus Medtech's price fluctuation is out of control at this time. Calculation of the real value of Venus Medtech is based on 3 months time horizon. Increasing Venus Medtech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Venus pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Venus Medtech. Since Venus Medtech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Venus Pink Sheet. However, Venus Medtech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  0.27 Real  0.26 Hype  0.27 Naive  0.28
The real value of Venus Pink Sheet, also known as its intrinsic value, is the underlying worth of Venus Medtech Company, which is reflected in its stock price. It is based on Venus Medtech's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Venus Medtech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
0.26
Real Value
5.83
Upside
Estimating the potential upside or downside of Venus Medtech helps investors to forecast how Venus pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Venus Medtech more accurately as focusing exclusively on Venus Medtech's fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.190.320.46
Details
Hype
Prediction
LowEstimatedHigh
0.010.275.84
Details
Naive
Forecast
LowNext ValueHigh
0.010.285.85
Details

Venus Medtech Total Value Analysis

Venus Medtech is at this time forecasted to have takeover price of 550.27 M with market capitalization of 855.6 M, debt of 70.78 M, and cash on hands of 2.96 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Venus Medtech fundamentals before making investing decisions based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
550.27 M
855.6 M
70.78 M
2.96 B

Venus Medtech Investor Information

About 22.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 1.08. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Venus Medtech recorded a loss per share of 0.13. The entity had not issued any dividends in recent years. Venus Medtech is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.

Venus Medtech Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Venus Medtech has an asset utilization ratio of 8.14 percent. This implies that the Company is making $0.0814 for each dollar of assets. An increasing asset utilization means that Venus Medtech is more efficient with each dollar of assets it utilizes for everyday operations.

Venus Medtech Ownership Allocation

Venus Medtech shows a total of 441.01 Million outstanding shares. Venus Medtech maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.

Venus Medtech Profitability Analysis

The company reported the revenue of 415.86 M. Net Loss for the year was (373.64 M) with profit before overhead, payroll, taxes, and interest of 324.34 M.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Venus Medtech's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Venus Medtech and how it compares across the competition.

About Venus Medtech Valuation

The pink sheet valuation mechanism determines Venus Medtech's current worth on a weekly basis. Our valuation model uses a comparative analysis of Venus Medtech. We calculate exposure to Venus Medtech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Venus Medtech's related companies.
Venus Medtech Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company was founded in 2009 and is headquartered in Hangzhou, the Peoples Republic of China. Venus Medtech operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 905 people.

8 Steps to conduct Venus Medtech's Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Venus Medtech's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Venus Medtech's valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain Venus Medtech's financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine Venus Medtech's revenue streams: Identify Venus Medtech's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research Venus Medtech's industry and market trends, including the size of the market, growth rate, and competition.
  • Establish Venus Medtech's growth potential: Evaluate Venus Medtech's management, business model, and growth potential.
  • Determine Venus Medtech's financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Venus Medtech's estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

Venus Medtech Growth Indicators

Investing in growth stocks can be very risky. If the company such as Venus Medtech does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding441 M
Forward Price Earnings77.5194
Retained Earnings-1.1 B

Complementary Tools for Venus Pink Sheet analysis

When running Venus Medtech's price analysis, check to measure Venus Medtech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Venus Medtech is operating at the current time. Most of Venus Medtech's value examination focuses on studying past and present price action to predict the probability of Venus Medtech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Venus Medtech's price. Additionally, you may evaluate how the addition of Venus Medtech to your portfolios can decrease your overall portfolio volatility.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Money Managers
Screen money managers from public funds and ETFs managed around the world
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Transaction History
View history of all your transactions and understand their impact on performance
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets